AMAR / MoH
Israel — AMAR / MoH
Medical Devices Law 5772-2012 + MoH Cybersecurity Circular
Authority
Medical Devices Division (AMAR), Israeli Ministry of Health
Enforced
2019 (cybersecurity circular)
Legal framework
Medical Devices Law + MoH Director-General Circulars + INCD guidance
Scope
All medical devices marketed in Israel; reference jurisdiction model accepts FDA, CE, Health Canada, TGA, PMDA approvals.
Pre-market
Cybersecurity risk management dossier, threat model, evidence of secure SDLC, alignment to FDA/IMDRF accepted.
Post-market
Adverse-event and cyber-incident reporting to MoH; coordination with INCD for critical infrastructure.
SBOM
RecommendedStrongly encouraged; aligned to FDA expectations for dual-market devices.
Vulnerability disclosure
INCD (Israel National Cyber Directorate) coordinated disclosure recommended.
Penalty
Registration suspension, recall orders, criminal liability under Medical Devices Law.
Unique requirements
- 01Israeli Registration Holder required
- 02Hebrew labelling for end users
- 03INCD critical-infrastructure notifications for hospital systems
Highlights
- Reference-jurisdiction abridged route
- INCD overlay for hospital-deployed devices
- Strong alignment to FDA SPDF
Aligns with
Timeline
-
2012
Medical Devices Law enacted
-
2019
MoH cybersecurity circular issued
-
2023
Updated alignment with FDA / IMDRF
Key documents
Related markets
Frequently asked about Israel
Is SBOM required for medical devices in Israel?
Recommended. Strongly encouraged; aligned to FDA expectations for dual-market devices.
What does AMAR / MoH require for pre-market cybersecurity?
Cybersecurity risk management dossier, threat model, evidence of secure SDLC, alignment to FDA/IMDRF accepted.
What are the post-market cybersecurity obligations under AMAR / MoH?
Adverse-event and cyber-incident reporting to MoH; coordination with INCD for critical infrastructure.
What is the penalty for non-compliance with AMAR / MoH cybersecurity rules?
Registration suspension, recall orders, criminal liability under Medical Devices Law.
How much of my FDA cybersecurity package is reusable in Israel?
Roughly 90% — an editorial estimate based on overlapping evidence requirements (threat model, SBOM, security risk assessment, pen-test report).